Eden Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.7/10
Best for: coverage in all 50 states, which most of the register will not confirm
Eden falls below our bar on medical oversight. Read the breakdown below before you give it money.
then $239/mo ongoing
Covered by the monthly price
Medication
In the price
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Eden is a premium telehealth platform. Its headline rates on both semaglutide and tirzepatide are promotional first-month prices.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Eden
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Eden at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $189/mo
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Shipping
- Availability
- All 50 states
- FDA status
- 1 FDA warning letter on record — see below
How Eden scores
Six columns, each one computed from something Eden has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
5.5/101 FDA warning letter on record; does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
4.5/10The price covers medication, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Eden
Last checked July 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Eden involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Eden publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Eden does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, shipping.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- Coverage is published for all 50 states.
- 1 FDA warning letter on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
GLP-1 medications Eden offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides Eden offers
Eden sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off Eden's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication and shipping
- Coverage is published for all 50 states
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Eden charges
Two numbers matter here and only one of them is the price. $189 is the opening month; $239/month is what Eden charges thereafter.
- Compounded semaglutide — $189 first month, then $239/month
- Compounded tirzepatide — $299 first month, then $349/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Discounting the first month does not change the twelve-month total by much.
Breeze Meds dispenses semaglutide and tirzepatide from $199/month, which makes it the honest comparison to run before committing here.
What Eden dispenses
Eden prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.
What we could verify
On the record: it treats patients in all 50 states. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- you want the price to stop moving as your dose climbs
- you want a cheap way to find out whether the medication suits you before committing
- you need access regardless of where you live
Our read
Eden is a cheap way to start and an ordinary way to continue. Use the $189 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $239/month before you let it renew twice. Direct Meds is the nearest comparison we track, and worth reading alongside this. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
Eden falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Eden
Starting at $189/month. Check today's price, then book the free consultation.
Where Eden is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Eden has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Eden review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Eden's current pricing
Plans start at $189/month. The free consultation is where you learn whether you qualify, and what it costs today.